Our Take
Two mature software vendors are consolidating under private equity, not shipping a new product or capability—this is a portfolio play, not a technical inflection.
Why it matters
Simulations Plus serves large pharma and regulators with established tools (GastroPlus, Monolix, ADMET Predictor). The deal signals continued consolidation in life sciences software, where subscription and cloud adoption are now table stakes and margins matter more than feature parity.
Do this week
Pharma CIOs: audit existing Simulations Plus or CCG contracts for renewal terms and vendor-lock clauses before Q4 2026 close, so you can negotiate migration optionality or multi-year discounts now.
Altaris closes $375M acquisition of Simulations Plus
Altaris, a life sciences-focused private equity firm, has signed a definitive agreement to buy Simulations Plus for approximately $375M in all-cash, with closing expected in Q4 2026. Shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of June 15, 2026 (company-reported). The deal remains subject to shareholder and regulatory approval.
Once closed, Simulations Plus will become a privately held subsidiary of Altaris and delist from Nasdaq. Its Research Triangle Park headquarters will remain unchanged. Altaris plans to merge Simulations Plus with Chemical Computing Group (CCG), another portfolio company that develops molecular design software—specifically the molecular operating environment, a tool adopted across biopharma for more than 30 years.
Simulations Plus develops model-informed, AI-driven drug development software. Its product portfolio includes GastroPlus (for physiologically-based pharmacokinetics), the Monolix Suite (population pharmacokinetics and pharmacodynamics), ADMET Predictor (absorption, distribution, metabolism, excretion), and quantitative systems pharmacology/toxicology (QSP/QST) platforms. These tools are widely used by large pharmaceutical companies, contract research organizations, and regulatory agencies.
The combination aims to build what Altaris describes as a more comprehensive biosimulation platform spanning the full drug discovery and development lifecycle. CEO Shawn O'Connor framed the rationale: "The life sciences industry is at an inflexion point, as software and services are rapidly evolving toward integrated, AI-driven platforms, cloud-based infrastructure, and more predictable, subscription-based business models."
Consolidation reflects margin pressure and platform expectations
This is a straightforward portfolio consolidation, not a breakthrough in modeling capability or a new product launch. Neither Simulations Plus nor CCG has announced independent benchmarks showing improved accuracy, speed, or cost-per-simulation. The deal rationale rests on business model convergence: cloud delivery, subscription pricing, and integrated workflows—expectations that are now baseline in enterprise life sciences software, not competitive moats.
The timing reflects a broader shift. Pharma increasingly expects single-vendor stacks that reduce integration friction and support AI-augmented workflows across discovery, candidate selection, and regulatory submission. Two complementary but separate tools (molecular design + PBPK modeling) become one vendor relationship, one contract, one roadmap. That simplification is valuable to customers, but it is not a capability jump.
For Altaris, the play is margin expansion and revenue consolidation. Simulations Plus and CCG likely have overlapping customer bases and complementary capabilities; combining them reduces sales overhead, cross-sells modules to existing clients, and positions the merged entity as a stronger acquisition target for a larger pharma software roll-up (or a holding for eventual IPO or secondary sale).
What customers and competitors should watch
Pharma operations teams and biotech CIOs should review existing contracts with both Simulations Plus and CCG before Q4 2026. Private equity ownership typically means two priorities: revenue expansion and cost efficiency. Expect either integration pressure (consolidating duplicate seats or modules) or price increases justified by "enhanced platform value." Lock in multi-year terms or negotiate migration flexibility now if you want optionality later.
Competitors in QSP, PBPK, and molecular design software (Certara, Schrödinger, Exscientia, and open-source alternatives like PumasAI) should monitor how the combined entity prices and bundles products. If Altaris bundles ADMET + CCG's MOE + QSP at a lower all-in cost than buying point solutions, it may shift customer procurement toward integrated stacks rather than best-of-breed. Integration timelines and product roadmap transparency will determine whether any customers view the transition as a risk or an opportunity to standardize.